Loading…
Loading…
ALMR (Alamar Biosciences, Inc.) is a recent IPO.
It began trading on April 17, 2026, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates. The affected sections are flagged individually so you can tell limited history from missing data.
Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now exceeding half of total revenue. Gross margin improved to 60% on manufacturing efficiencies and consumables mix, but high operating expenses maintain losses amid aggressive investment.
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.
Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities.
Alamar Biosciences (NASDAQ: ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering. Chief Executive Officer Yuling Luo said the quarter reflected continued adoption of the company's precision